文献速递前列腺癌

靶向穿刺时代活检与根治性前列腺切除病理的一致性:系统综述与Meta分析

Concordance Between Biopsy and Radical Prostatectomy Pathology in the Era of Targeted Biopsy: A Systematic Review and Meta-analysis.
PubMed 文献 · Eur Urol Oncol · 2019-09-04

该系统综述与Meta分析纳入10项研究共1215名男性,比较mpMRI靶向经直肠前列腺穿刺(TBx)与系统经直肠前列腺穿刺(SBx)病理与根治性前列腺切除病理的一致性。结果显示SBx病理升级风险显著高于TBx(OR 2.47,95%CI 1.48-4.14,p=0.001),而降级风险无显著差异。结论认为TBx对Gleason评分评估更准确。

要点

  • SBx病理升级风险显著高于TBx(OR 2.47)。
  • TBx与SBx降级风险无显著差异(OR 1.13)。
  • 初穿和既往阴性者中SBx升级风险均高于TBx。

核心结论

  • 与系统穿刺相比,mpMRI靶向穿刺病理升级可能性更低,且不增加降级风险。
  • 靶向穿刺对根治性前列腺切除Gleason评分评估更准确,可提高基于其病理的管理决策信心。

研究设计与样本

  • 系统综述与Meta分析,检索Ovid MEDLINE、Ovid EMBASE、Cochrane Library和EBSCHOHost从建库至2018年7月。
  • 纳入2012年后发表、同时行SBx和TBx、且≥50例患者比较活检与根治性前列腺切除病理的研究。
  • 共纳入10项研究包括1215名男性;中位年龄65岁,中位前列腺特异性抗原7.2 ng/ml。
  • 采用PRISMA指南,使用QUADAS-2工具评估偏倚。

主要发现

  • 在8项评估根治性前列腺切除病理升级的研究中,SBx病理升级风险显著高于TBx(OR 2.47,95%CI 1.48-4.14,p=0.001)。
  • TBx与SBx降级风险无显著差异(OR 1.13,95%CI 0.48-2.67,p=0.783)。
  • 初穿男性中SBx升级风险高于TBx(OR 1.6,95%CI 1.02-2.27,p<0.001)。
  • 既往阴性活检男性中SBx升级风险高于TBx(OR 4.23,95%CI 1.68-8.48,p=0.003)。

临床怎么用

  • 基于mpMRI靶向穿刺病理制定管理决策时,可对Gleason评分准确性有更高信心。
  • 在初穿和既往阴性活检男性中,靶向穿刺较系统穿刺更能减少病理升级。

局限性

  • 纳入标准仅适用于这些研究中部分男性。
  • 检索截止2018年7月,未涵盖此后证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Multiparametric magnetic resonance imaging (mpMRI)-targeted transrectal prostate biopsy (TBx) may better predict pathology at radical prostatectomy than systematic transrectal prostate biopsy (SBx). OBJECTIVE: To assess concordance between biopsy and radical prostatectomy pathology in men undergoing a TBx as compared with those undergoing an SBx. EVIDENCE ACQUISITION: Four electronic databases (Ovid MEDLINE, Ovid EMBASE, the Cochrane Library [Wiley], and EBSCHOHost) were searched from inception until July 2018. Studies were included if they were published after 2012, conducted both SBx and TBx, and compared the biopsy results with final pathology after radical prostatectomy for ≥50 patients. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were utilized. Bias was appraised using the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) tool. EVIDENCE SYNTHESIS: Our search yielded 10 studies including 1215 men. However, our inclusion criteria applied only to a proportion of men included in these studies. The median age was 65 yr and the median prostate-specific antigen level was 7.2 ng/ml. In the eight studies examining upgrading at prostatectomy, pathology from SBx was significantly more likely to be upgraded relative to TBx (odds ratio [OR] 2.47, 95% confidence interval [CI] 1.48-4.14, p = 0.001). We found no significant difference in downgrading (OR 1.13, 95% CI 0.48-2.67, p = 0.783) between TBx and SBx. For both biopsy-naïve men and men with a prior negative biopsy, results from SBx were more likely to be upgraded than TBx at prostatectomy (OR 1.6 [95% CI 1.02-2.27, p < 0.001] and OR 4.23 [95% CI 1.68-8.48, p = 0.003], respectively). CONCLUSIONS: Pathologic upgrading at prostatectomy was less likely with mpMRI-targeted biopsy versus systematic biopsy alone, without concurrent increase in downgrading. This increased accuracy should improve confidence in management decisions based on MRI-targeted biopsy pathology. PATIENT SUMMARY: We reviewed the ability of multiparametric magnetic resonance imaging -targeted biopsy to predict cancer grade at radical prostatectomy. We found that targeted biopsy provides more accurate assessment of Gleason score at prostatectomy than systematic biopsy.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Goel S, Shoag JE, Gross MD, et al. Concordance Between Biopsy and Radical Prostatectomy Pathology in the Era of Targeted Biopsy: A Systematic Review and Meta-analysis. Eur Urol Oncol. 2019. PMID: 31492650. doi:10.1016/j.euo.2019.08.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。